Latest news with #Poisoning
Fox News
2 days ago
- Health
- Fox News
Nicotine pouches pose alarming danger in US households, experts warn
Nicotine pouches present a heightened danger to children, according to a recent study from the Abigail Wexner Research Institute at Nationwide Children's Hospital (NCH) in Columbus, Ohio. The pouches contain a dissolving powder made of nicotine and flavorings that gets absorbed through the gums and lining of the mouth, according to the Centers for Disease Control and Prevention. The research, published by the American Academy of Pediatrics, found that there were 134,663 reported cases of ingestion of pouches, vapes and other nicotine products among children between 2010 and 2023. Researchers analyzed calls to the National Poison Data System related to accidental nicotine ingestions among children younger than 6 years old. Ingestion of the pouches soared by 763% from 2020 to 2023, as they were up to twice as likely to result in serious medical outcomes than other nicotine products, such as gum/lozenges, liquids, powder/granules and tablets/capsules/caplets. Gary Smith, M.D., director of the Center for Injury Research and Policy at NCH, told Fox News Digital that nicotine pouches were not tracked in national poison center data until 2020. "However, between 2020 and 2023 (the most recent year of data from the study), the rate of unintentional ingestion of nicotine pouches by young children increased at a fast rate — even as ingestion rates for other formulations of nicotine declined," he said. The study found a 59% increase in nicotine ingestions between 2010 and 2015, which was primarily driven by liquid and solid nicotine products. From 2015 to 2023, liquid nicotine ingestion dropped by 45%, leading to a 34% reduction in overall nicotine ingestion incidents. The study had several limitations, Smith shared, one being that the National Poison Data System is a "passive surveillance system and therefore underestimates the true number of nicotine ingestions among U.S. children younger than 6 years old." "Because data are self-reported, they cannot be completely verified by poison centers," he added. Smith also pointed out that the study did not analyze nicotine dosage, and that there is the possibility of "miscategorization of data and missing data." Smith noted that the overall decline in nicotine ingestion could be linked to the passage of federal and state legislation. In 2015, Congress passed the Child Nicotine Poisoning Prevention Act, which made it a law for liquid nicotine packaging to be child-resistant. "This suggests that legislation can make a difference," Smith said. There are opportunities for further improvement in terms of passing preventative laws, the researcher noted. "Many nicotine products are flavored and sold in colorful packaging that may be attractive to a young child," he cautioned. "Banning flavors in all nicotine products would help reduce unintentional ingestions by young children as well as discourage use among teens." Given that nicotine pouches present a "serious and growing toxic ingestion hazard" among young children, Smith calls for ongoing surveillance and prevention efforts. "Many nicotine products are flavored and sold in colorful packaging that may be attractive to a young child." The effects of nicotine toxicity include nausea, vomiting, high blood pressure, fast heart rate, seizures, trouble breathing, coma and death, he told Fox News Digital. For more Health articles, visit Parents who suspect that a child has ingested a nicotine pouch should call the national Poison Help number at 1-800-222-1222, Smith advised. "The safest choice is to keep all nicotine products out of the home," he said. Otherwise, they should be stored safely and out of reach.
Yahoo
16-05-2025
- Health
- Yahoo
REM Poisoning Pipeline Market Research Report 2025: In-Depth Commercial and Clinical Assessment
The "REM Poisoning Pipeline Insight, 2025" report provides a comprehensive overview of the REM Poisoning market, covering drug development from pre-clinical phases to market readiness. It includes detailed analyses of therapeutic pipelines, collaborations, and licensing, alongside market growth prospects driven by emerging therapies. Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "REM Poisoning - Pipeline Insight, 2025" has been added to offering. 'REM Poisoning Pipeline Insight, 2025' delivers an in-depth analysis of the current clinical development and future growth prospects of the REM Poisoning market. The report comprehensively covers the REM poisoning pipeline landscape, addressing both disease overviews and treatment guidelines. It includes a detailed commercial and clinical assessment of pipeline products, spanning from pre-clinical phases to marketed stages. Each drug's description contains mechanisms of action, clinical study details, NDA approvals, product development activities, and collaborations. Pipeline Development Activities The report examines companies developing REM Poisoning therapies, elaborating on the aggregate therapies each company has under development. It segments therapeutic candidates into early-stage, mid-stage, and late-stage development, detailing active and inactive (dormant or discontinued) projects. Drugs under development are analyzed by development stage, administration route, target receptor, monotherapy or combination therapy, mechanism of action, and molecular type. The report includes detailed analyses of company-company and company-academia collaborations, as well as licensing agreements and financing, essential for advancing the REM Poisoning market. Analytical Perspective Commercial Assessment A comprehensive commercial assessment involves analyzing collaboration trends, licensing, and acquisition deal values. The report offers graphical and tabulated presentations of company collaborations, both industry and academia, along with acquisition analyses. Clinical Assessment The report presents a comparative clinical assessment of products categorized by development stage, product type, administration route, molecule type, and mechanism of action. Scope of the Report The document provides an overview of the therapeutic pipeline, assessing products by development stage, product type, administration route, molecule type, and mechanism of action. It also maps out the complete product development cycle, from nonclinical to clinical stages. Detailed profiles of therapeutic products cover developmental activities such as technology, collaborations, licensing, mergers and acquisitions, funding, and designations. The report also reviews the progress in research and development, trial details, and results. Coverage of dormant and discontinued projects, with explanations where available, is included as well. Report Highlights Improved understanding of the disease pathogenesis can lead to novel therapeutics for REM Poisoning, and the market is expected to evolve with increased disease awareness and healthcare spending. The involvement of pharmaceuticals in the REM Poisoning treatment market shows promise, as several emerging therapies under investigation could significantly impact the market size. Our analysis of pipeline assets supports client decision-making in therapeutic portfolios by identifying the current R&D landscape. Key Topics Covered: 1. Report Introduction 2. REM Poisoning2.1. Overview2.2. History2.3. REM Poisoning Symptoms2.4. Causes2.5. Pathophysiology2.6. REM Poisoning Diagnosis2.6.1. Diagnostic Guidelines 3. REM Poisoning Current Treatment Patterns3.1. REM Poisoning Treatment Guidelines 4. REM Poisoning - The Publisher's Analytical Perspective4.1. In-depth Commercial Assessment4.1.1. REM Poisoning companies collaborations, Licensing, Acquisition -Deal Value Trends4.1.2. REM Poisoning Collaboration Deals 5. Therapeutic Assessment5.1. Clinical Assessment of Pipeline Drugs 6. REM Poisoning Late Stage Products (Phase-III) 7. REM Poisoning Mid Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. REM Poisoning Discontinued Products 13. REM Poisoning Product Profiles13.1. Drug Name: Company13.1.1. Product Description13.1.2. Research and Development13.1.3. Product Development Activities13.1.4. Tabulated Product Summary 14. REM Poisoning Key Companies 15. REM Poisoning Key Products 16. Dormant and Discontinued Products16.1. Dormant Products16.2. Discontinued Products 17. REM Poisoning Unmet Needs 18. REM Poisoning Future Perspectives 19. REM Poisoning Analyst Review 20. Appendix For more information about this drug pipelines report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
